drugset

drugset / Trial / NCT07185269

The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE

NCT07185269 ↗

Phase 1/2 Recruiting 198 enrolled Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the effect and safety of 626 in patients with SLE

Timeline

Start: 2025-09-24
Primary completion: 2028-08-12
Completion: 2028-11-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	626	Unknown	—	Subcutaneous

Indications